Patents
Literature
Eureka-AI is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Eureka AI

760 results about "Anti cancer drugs" patented technology

Temoside (Temozolomide) is an oral anti-cancer drug that is used in chemotherapy. This drug is used for the treatment of certain types of brain tumors. It is sometimes used for the treatment of bone cancer that has come back.

Copper sulfide/mesoporous silicon dioxide core-shell nano material as well as preparation method and application thereof

The invention relates to a copper sulfide/mesoporous silicon dioxide core-shell nano material as well as a preparation method and an application thereof. The chemical formula of the core-shell nano material is Cu9S5/mSiO2-PEG. The preparation method comprises the following steps of: (1) raising the temperature of oleylamine under the protection of nitrogen; adding a mixed solution of copper dibutyldithiocarbamate and the oleylamine and dispersing the mixed solution into chloroform to prepare a D solution; (2) dissolving a surfactant into water; raising the temperature and adding the D solution to prepare an E solution; and (3) taking the E solution and adding ethanol; raising the temperature and adding an NaOH solution; immediately adding TEOS (Tetraethylorthosilicate) and reacting; adding PEG-silane; continually reacting and carrying out hydrothermal reaction; and adding into a scrubbing solution to centrifuge and wash to obtain the product. The copper sulfide/mesoporous silicon dioxide core-shell nano material is applied to near-infrared photo-thermal treatment, anti-cancer drugs, chemotherapy of tumors and infrared heat imaging. The nano material disclosed by the invention has very low cell toxicity and very high blood compatibility; and the united effects of thermal therapy and the chemotherapy are good.
Owner:DONGHUA UNIV

Nano-drug carrier with magnetothermal and photothermal effects and preparation method thereof

The invention discloses a nano-drug carrier with the magnetothermal and photothermal effects. The particle size is 50 nanometers to 300 nanometers, and the nano-drug carrier is prepared from mesoporous silica particles, Fe3O4 nanoparticles embedded into the mesoporous silica particles and graphene oxide with which the surfaces of the mesoporous silica particles are coated. The invention further provides a preparation method of the nano-drug carrier. The superparamagnetic Fe3O4 nanoparticles are prepared through a solvothermal method, the Fe3O4 nanoparticles are composited by taking hexadecyl trimethyl ammonium bromide as a structure-directing agent and taking tetraethoxysilane as a silicon source through the sol-gel self-assembling process, and then magnetic mesoporous nanoparticles Fe3O4/mSiO2 with the magnetic property adjustable and controllable are prepared; the surfaces of the Fe3O4/mSiO2 mesoporous nanoparticles are coated with graphene through the ion interaction or electrostatic interaction or hydrogen-bond interaction, and then the nano-drug carrier which both can efficiently deliver anti-cancer drugs and has the magnetothermal and photothermal effects is obtained. Accordingly, cancer treatment in which medical chemotherapy cooperates with magnetothermal and photothermal treatment can be achieved.
Owner:UNIV OF SHANGHAI FOR SCI & TECH

Nano particle-polymer injectable composite hydrogel double drug loading system and preparation method thereof

The invention belongs to the field of synthesis of drug carrier base materials and provides a nano particle-polymer injectable composite hydrogel double drug loading system and a preparation method thereof. The double drug loading system is loaded with not only an anti-cancer drug I of which polymer nano particles are synthesized through a disulfide bond cross-linking agent by taking acrylic acidand 4-vinylphenylboric acid as monomers, but also an anti-cancer drug II of which injectable hydrogel is synthesized through Michael addition reaction between a macromolecular cross-linking agent witha sulfhydryl functional group and a polymer containing a catechol functional group aiming at the drug loading capacity, the action time, the treatment effect and other demands. The bi-stimulus response is pH stimulus response and reducing stimulus response of glutathione to the disulfide bond cross-linking agent in a tumor cell environment respectively, the interaction between the nano particlesand the drug I as well as the degradation process of the nano particle can be affected, and the long-term delivery of the drug I is realized. The nano particle-polymer injectable composite hydrogel double drug loading system provided by the invention realizes the effects of local long-time administration, step-by-step osmotic treatment and combined treatment of a variety of drugs.
Owner:NANJING UNIV OF POSTS & TELECOMM

Tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system, as well as preparation method and application thereof

InactiveCN104174027APromote endocytosisIncrease effective drug concentrationOrganic active ingredientsHeavy metal active ingredientsSide effectTreatment effect
The invention relates to a tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system, as well as a preparation method and application thereof. The tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system comprises mesoporous silica nano-particles, RGD polypeptide which is linked to the surfaces of the mesoporous silica nano-particles in a covalent manner and serves as a tumor vessel/tumor cell membrane targeting ligand, and a nuclear localization signal polypeptide sequence serving as a cell nucleus targeting ligand. Under the condition of intravenous injection, the drug-loaded system can be enriched in a tumor tissue by means of the targeting effect of the tumor vessel to reduce the uptake of normal tissues and reduce toxic and side effect, is capable of increasing the phagocytosis amount of tumor cells by means of the identification effect on the tumor cell membrane, and can be used for directly delivering anti-cancer drugs into a cell nucleus by means of the delivery performance of the cell nucleus to increase the concentration of effective drugs, so that an optimal treatment effect can be achieved.
Owner:SHANGHAI INST OF CERAMIC CHEM & TECH CHINESE ACAD OF SCI

New synthesis technology of anti-cancer drug Raltitrexed

The invention relates to a new synthesis technology of anti-cancer drug Raltitrexed. The technology comprises the following steps: 1) using L-glutamic acid as raw material to perform esterification with alcohol under the action of halogenating agent and obtain L-glutamic acid diester hydrochloride; 2) using 2-amino-5-methyl-benzoic acid as raw material to prepare 6-bromomethyl-3,4-dihydro-2-methyl-4-oxo-6-quinazoline through cyclization, amination and bromination; 3) using 2-thienyl-propanedioic acid as raw material to prepare N-[5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thenoyl]-L-glutamic acid diethyl ester through nitrification, esterification, reduction, amino protection, N-methylation and device-esterification; 4) using L-glutamic acid diester hydrochloride and N-[5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thenoyl]-L-glutamic acid diethyl ester to prepare N-[5-(N-methylamino)-2-thenoyl]-L-glutamic acid diester through dehydrant condensation and deamination protection; and 5) using N-[5-(N-methylamino)-2-thenoyl]-L-glutamic acid diester and 6-bromomethyl-3,4-dihydro-2-methyl-4-oxo-6-quinazoline to perform condensation under the catalysis of alkali, recycling preparative chromatography, purifying, and performing de-esterification to obtain Raltitrexed.
Owner:深圳市普迈达科技有限公司

Anticancer sustained release agent containing epothilone

Disclosed is an anti-cancer drugs slow release agent containing Epothilone which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer active constituents include Epothilone, Epothilone derivatives, Epothilone B, Epothilone D and combination of anti-cancer drugs selected from phosphoinositide-3-kinase inhibitor, of pyrimidine analogues and/or DNA restoring enzyme inhibitor, the slow release auxiliary materials include polylactic acid and its copolymer, polyethylene glycol, PLA-COOH copolymer, di-aliphatic acid and sebacylic acid copolymer, poly(erucic aciddipolymer-sebacylic acid), poly(fumaric acid-sebacylic acid), Polifeprosan, polylactic acid and other biocompatible high polymers, the viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose. The anticancer active constituents and the slow release microspheres can also be prepared into slow release implanting agent for intra-tumor or around-tumor injection or placement for the effective suppression of tumor growth and for the appreciable enhancement for curative effects of non-operative treatments such as chemotherapy.
Owner:JINAN SHUAIHUA PHARMA TECH

Anti-cancer sustained-released injection containing epothilone derivate

The invention relates to an anti-cancer sustained release injection containing epothilone derivative, consisting of sustained microspheres and menstruum. The sustained microspheres comprise anti-cancer drugs selected from taxane, alkylating agent and/or plant alkaloid and the like, the epothilone derivative and sustained release auxiliary material. The menstruum is a special menstruum containing suspending agent. The epothilone derivative is selected from epothilone B, epothilone D, iso-epothilone D, BMS-247550, azaepothilone B, furan epothilone D or BMS-310705. The sustained release auxiliary material is selected from poly-dl-lactide, the glycolic acid copolymer of the poly-dl-lactide, polyethyleneglycol, the polylactide copolymer of the polyethyleneglycol, carboxyl terminated polylactide copolymer, fatty acid and decanedioic acid copolymer, etc. The suspending agent is selected from carboxymethyl cellulose and the like with the viscosity of 100cp to 3000cp (under the temperature of 25 DEG C to 30 DEG C). The sustained release microsphere can also be made into a sustained release implant. The sustained release injection is injected or arranged in or around the tumour and can release drug at partial position for 40 days approximately, therefore, the sustained release injection improves the local drug concentration selectively and enhances the treatment effect of non-operative treatments, such as radiotherapy, chemotherapy and the like at the same time.
Owner:JINAN SHUAIHUA PHARMA TECH

Anti-cancer sustained-released injection containing epothilone derivate

The invention relates to an anti-cancer sustained release injection containing epothilone derivative, consisting of sustained microspheres and menstruum. The sustained microspheres comprise anti-cancer drugs selected from taxane, alkylating agent and/or plant alkaloid and the like, the epothilone derivative and sustained release auxiliary material. The menstruum is a special menstruum containing suspending agent. The epothilone derivative is selected from epothilone B, epothilone D, iso-epothilone D, BMS-247550, azaepothilone B, furan epothilone D or BMS-310705. The sustained release auxiliary material is selected from poly-dl-lactide, the glycolic acid copolymer of the poly-dl-lactide, polyethyleneglycol, the polylactide copolymer of the polyethyleneglycol, carboxyl terminated polylactide copolymer, fatty acid and decanedioic acid copolymer, etc. The suspending agent is selected from carboxymethyl cellulose and the like with the viscosity of 100cp to 3000cp (under the temperature of 25 DEG C to 30 DEG C). The sustained release microsphere can also be made into a sustained release implant. The sustained release injection is injected or arranged in or around the tumour and can release drug at partial position for 40 days approximately, therefore, the sustained release injection improves the local drug concentration selectively and enhances the treatment effect of non-operative treatments, such as radiotherapy, chemotherapy and the like at the same time.
Owner:JINAN SHUAIHUA PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products